Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O'Day, Sandra Horning, Michael Varney

Following Roche's successful tender offer for a majority of Foundation Medicine shares, Daniel O'Day, Sandra Horning, and Michael Varney have joined Foundation Medicine's board of directors.

O’Day is the chief operating officer of the Roche Pharmaceuticals division and a member of the Roche corporate executive committee, Horning is the global head of product development and chief medical officer for Roche's Genentech, and Varney is the head of Genentech research and early development.

The three new directors are joining five continuing directors: Foundation Medicine CEO Michael Pellini; Alexis Borisy, who will remain the board's chairman; Evan Jones; David Schenkein; and Krishna Yeshwant.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.